Subregional neuroanatomical change as a biomarker for Alzheimer's disease
Authors:
- Dominic HollandDHDominic Holland
- Christine Fennema-NotestineCFChristine Fennema-Notestine
- The Alzheimer'S Disease Neuroimaging InitiativeTIThe Alzheimer'S Disease Neuroimaging Initiative
- Michael WeinerMWMichael Weiner
- Leon ThalLTLeon Thal
- Ronald PetersenRPRonald Petersen
- Clifford R. JackCJClifford R. Jack
- William JagustWJWilliam Jagust
- John TrojanowkiJTJohn Trojanowki
- 8 December 2009
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (49) , 20954-20959
Abstract
Regions of the temporal and parietal lobes are particularly damaged in Alzheimer's disease (AD), and this leads to a predictable pattern of brain atrophy. In vivo quantification of subregional atrophy, such as changes in cortical thickness or structure volume, could lead to improved diagnosis and better assessment of the neuroprotective effects of a therapy. Toward this end, we have developed a fast and robust method for accurately quantifying cerebral structural changes in several cortical and subcortical regions using serial MRI scans. In 169 healthy controls, 299 subjects with mild cognitive impairment (MCI), and 129 subjects with AD, we measured rates of subregional cerebral volume change for each cohort and performed power calculations to identify regions that would provide the most sensitive outcome measures in clinical trials of disease-modifying agents. Consistent with regional specificity of AD, temporal-lobe cortical regions showed the greatest disease-related changes and significantly outperformed any of the clinical or cognitive measures examined for both AD and MCI. Global measures of change in brain structure, including whole-brain and ventricular volumes, were also elevated in AD and MCI, but were less salient when compared to changes in normal subjects. Therefore, these biomarkers are less powerful for quantifying disease-modifying effects of compounds that target AD pathology. The findings indicate that regional temporal lobe cortical changes would have great utility as outcome measures in clinical trials and may also have utility in clinical practice for aiding early diagnosis of neurodegenerative disease.Keywords
This publication has 57 references indexed in Scilit:
- PROMO: Real‐time prospective motion correction in MRI using image‐based trackingMagnetic Resonance in Medicine, 2009
- Regional rates of neocortical atrophy from normal aging to early Alzheimer diseaseNeurology, 2009
- Alzheimer Disease: Quantitative Structural Neuroimaging for Detection and Prediction of Clinical and Structural Changes in Mild Cognitive ImpairmentRadiology, 2009
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's diseaseBrain, 2009
- Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezilBMC Neurology, 2009
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methodsJournal of Magnetic Resonance Imaging, 2008
- Prognostic Value of Posteromedial Cortex Deactivation in Mild Cognitive ImpairmentPLOS ONE, 2007
- Cortical Surface-Based AnalysisNeuroImage, 1999
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982